GlassScriptPhysician profile
Naman D Dalal
NPI 1942732375
$4,172.94
in general payments reported to CMS, 2019-2025
30 companies · $1,094 in 2025
The $1,094 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.45 · 2022: $678 · 2023: $1,104 · 2024: $1,278 · 2025: $1,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,475.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $775.70 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $611.67 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $465.53 | 2022-2025 | |
| Glaxosmithkline, LLC. | $344.48 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $327.22 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $227.05 | 2022-2025 | Qulipta, Ubrelvy |
| Amgen INC. | $210.23 | 2022-2025 | Otezla, Repatha, Otezla |
| Abbott Laboratories | $137.26 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.10 | 2022-2025 | Jardiance |
| Exact Sciences Corporation | $120.97 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Daiichi Sankyo INC. | $120.49 | 2022-2024 | Injectafer |
| Merck Sharp & Dohme LLC | $99.14 | 2023-2025 | Gardasil 9, Capvaxive, Gardasil |
| Biohaven Pharmaceutical Holding Company LTD. | $81.94 | 2022 | |
| Antares Pharma, INC. | $69.59 | 2022-2023 | Nocdurna, Xyosted, Tlando |
| Phathom Pharmaceuticals, INC. | $63.96 | 2024-2025 | Voquezna |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $48.33 | 2024-2025 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.77 | 2024-2025 | Xifaxan |
| Tolmar, INC. | $33.60 | 2025 | Jatenzo |
| Novartis Pharmaceuticals Corporation | $32.59 | 2022-2023 | |
| Aimmune Therapeutics, INC. | $26.79 | 2025 | Zenpep |
| Inspire Medical Systems, INC. | $24.24 | 2023 | Inspire |
| Dynavax Technologies Corporation | $24.12 | 2024 | Heplisav-B |
| Corcept Therapeutics | $23.59 | 2025 | Korlym |
| Phadia US INC. | $22.16 | 2024 | Immunocap |
| Bayer Healthcare Pharmaceuticals INC. | $22.14 | 2025 | |
| Dexcom, INC. | $21.29 | 2024 | Dexcom G6 Transmitter |
| Seqirus USA INC | $20.31 | 2025 | Flucelvax, Fluad |
| Allergan, INC. | $19.35 | 2022 | |
| Esperion Therapeutics, INC. | $14.92 | 2024 | Nexletol |
| Amneal Pharmaceuticals LLC | $14.41 | 2023 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naman Dalal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.